Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Tyra Biosciences Inc. (TYRA) stock has reached a 52-week low, touching down at $9.9 as the biotechnology sector faces headwinds. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 29.55 and holds more cash than debt on its balance sheet. This price level reflects a significant downturn from the company’s performance over the past year, with Tyra Biosciences experiencing a 1-year change of -33.72%. Investors are closely monitoring the company’s strategic moves and potential catalysts that could influence its stock price in the coming months, as it navigates through a challenging period marked by this notable decline. Despite current headwinds, analysts maintain a strong buy consensus with price targets ranging from $28 to $33. InvestingPro analysis suggests the stock is currently fairly valued, with additional insights available through their comprehensive financial analysis tools.
In other recent news, Tyra Biosciences has received FDA clearance to advance its drug candidate TYRA-300 into a Phase 2 clinical trial targeting low-grade, intermediate-risk non-muscle invasive bladder cancer. This trial, known as SURF302, will assess the efficacy and safety of TYRA-300 in patients with FGFR3-altered cancer, with plans to enroll up to 90 participants across multiple U.S. sites. Additionally, Tyra Biosciences announced the appointment of Adele Gulfo to its Board of Directors, bringing her extensive experience in the pharmaceutical industry to the company. This follows the resignation of Nina Kjellson from the board, with no disagreements cited regarding company operations or policies.
In analyst news, H.C. Wainwright reaffirmed its Buy rating for Tyra Biosciences with a $30 price target, citing confidence in TYRA-300 as a leading FGFR3 inhibitor. UBS also initiated coverage with a Buy rating and a $28 price target, expressing optimism about the long-term growth potential of TYRA-300. UBS highlighted the drug’s potential to lead the market in both oncology and growth disorder treatments, suggesting a significant revenue opportunity beyond current market expectations. Tyra Biosciences continues to focus on developing precision medicines, with its pipeline including three clinical-stage programs targeting oncology and genetically defined diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.